Neuracle Science Co., Ltd.

Neuracle Sceince, Inc.

Jae Young Seong

Eun Bee Cho

Jong Ik Hwang

Woong Sun

Won-Ki Kim

Bongcheol Kim

Dong-Hoon Kim

Junho Chung

Jee Youn Lee

Junyeong Jin

Tae Young Yune

Gi Hoon Son

Jong-Ik Hwang

Yoo-Na Lee

Seongsik Yun

Arfaxad Reyes-Alcaraz

Dong Sik Kim

Jae-Keun Lee

Shin-Hyuk Kang

Soon-gu Kwon

Juwon Shim

Tae Woo Kim

Nui Ha

Min-Hyeok Lee

Byung Joo Ham

The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.

Pharmaceutical use of FAM19A5 involved in regulating gliogenesis

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof

The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.

Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment and diagnosis of mood disorders

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.

Use of anti-FAM19A5 antibodies for treating cancers

The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.

Agonist of spexin-based galanin type 2 receptor and use thereof

Growing community of inventors

Seoul, South Korea

Jae Young Seong